Respiratory Syncytial Virus (RSV) Vaccines Market worth $1.24 billion by 2030
The report "Respiratory Syncytial Virus (RSV) Vaccines Market by Technology (Recombinant, Inactivated & Subunit, Others), Type (Monovalent, Multivalent), End User (Pediatric, Adult) & Region – Global Forecast to 2030" is projected to grow from USD 1.60 billion in 2025 and to reach USD 1.24 billion by 2030, at a Compound Annual Growth Rate (CAGR) of -4.9% during the forecast period.
Browse 400 market data Tables and 40 Figures spread through 350 Pages and in-depth TOC on "Respiratory Syncytial Virus (RSV) Vaccines Market by Technology (Recombinant, Inactivated & Subunit, Others), Type (Monovalent, Multivalent), End User (Pediatric, Adult) & Region – Global Forecast to 2030"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/respiratory-syncytial-virus-rsv-vaccines-market-91874426.html
The global respiratory syncytial virus (RSV) vaccine market is gaining traction due to the high disease burden among infants and older adults. A growing focus on preventive care is supporting early adoption across key regions. Recent advances in vaccine platforms have bolstered confidence in safety and efficacy. Together, these factors are strengthening RSV vaccination uptake globally.
The inactivated & subunit technology accounted for the largest share in the respiratory syncytial virus (RSV) vaccines market in 2024.
By technology, the RSV vaccine market is divided into Recombinant, Inactivated & Subunit, and Others. In 2024, the Inactivated & Subunit segment held the highest share of the RSV vaccine market. This is mainly due to the segment's significant revenue generation. Additionally, Inactivated & Subunit technologies are dominant because they offer proven safety profiles and are well understood by regulators and healthcare providers.
Pediatric vaccines are estimated to register the fastest growth in the respiratory syncytial virus (RSV) vaccines end user market during the forecast period of 2025-2030.
By end user, the market is divided into pediatric and adult vaccines. During the forecast period, pediatric vaccines experienced the fastest growth in the end-user RSV vaccines market. Pediatric RSV vaccines are the fastest-growing segment due to the high disease burden among infants and young children and the strong focus on early prevention.
North America accounted for the largest regional share in the RSV vaccines market in 2024.
The regional market for respiratory syncytial virus (RSV) vaccines is segmented into North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa. North America is the largest RSV vaccine market due to early product adoption, strong awareness among providers and patients, and clear immunization guidance for older adults and at-risk groups. Broad access through pharmacies and health systems supports high seasonal coverage.
Key players in the respiratory syncytial virus (RSV) vaccines market
About MarketsandMarkets™
MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.
Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.
The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook .
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the Respiratory Syncytial Virus (RSV) Vaccines Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
